血管扩张剂治疗严重心力衰竭的疗效已被公认,硝普钠能减轻心脏负荷,改善急性或慢性冠状动脉疾患、瓣膜病和心肌病所引起的心功能不全,其有益的血液动力学作用与周围阻力血管和容量血管平滑肌的松弛有关。由于它具有均衡扩张静脉床和动脉床的作用,因此在减轻心室前负荷的同时,主动脉阻抗下降,从而能同时减轻肺郁血和增加心排出量。但是,硝普钠只能静脉给予。Prazo—sin是一种新的口服扩张血管降压药,对小动脉床和静脉床具有均衡的扩张作用,本文旨在评定长期口服Prazosin对门诊慢性难治性充血性心力衰竭病人的疗效。方法:严重缺血性充血性心力衰竭病人 Therapeutic efficacy of vasodilators in the management of severe heart failure has been well recognized that sodium nitroprusside can reduce cardiac stress and improve cardiac insufficiency caused by acute or chronic coronary artery disease, valvular disease and cardiomyopathy with beneficial hemodynamic effects Resistance and relaxation of vascular smooth muscle capacity. Because of its balanced expansion of the venous bed and arterial bed, it reduces the preload of the ventricle and at the same time decreases the impedance of the aorta, thereby reducing both the blood stasis of the lung and the cardiac output. However, sodium nitroprusside can only be administered intravenously. Prazo-sin is a novel oral dilation vasopressor with a balanced expansion of the arteriolar bed and venous bed. This article aims to assess the efficacy of long-term oral Prazosin in outpatients with chronic refractory congestive heart failure. Methods: Patients with severe ischemic congestive heart failure